$TDOC
Teladoc Health, Inc.

2021 Q1 Form 10-Q Financial Statement

#000155837021005521 Filed on May 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $453.7M $180.8M
YoY Change 150.93% 40.62%
Cost Of Revenue $146.0M $72.38M
YoY Change 101.65% 62.01%
Gross Profit $307.7M $108.4M
YoY Change 183.83% 29.23%
Gross Profit Margin 67.83% 59.97%
Selling, General & Admin $170.0M $64.28M
YoY Change 164.41% 23.16%
% of Gross Profit 55.23% 59.29%
Research & Development $78.01M $19.26M
YoY Change 305.09% 20.45%
% of Gross Profit 25.35% 17.76%
Depreciation & Amortization $48.66M $9.710M
YoY Change 401.12% -16.03%
% of Gross Profit 15.81% 8.96%
Operating Expenses $248.0M $83.54M
YoY Change 196.84% 22.53%
Operating Profit -$84.68M -$21.01M
YoY Change 303.02% -8.2%
Interest Expense -$22.10M -$9.300M
YoY Change 137.63% 43.08%
% of Operating Profit
Other Income/Expense, Net $5.652M -$685.0K
YoY Change -925.11%
Pretax Income -$112.6M -$30.31M
YoY Change 271.48% 3.08%
Income Tax $87.00M -$700.0K
% Of Pretax Income
Net Earnings -$199.6M -$29.60M
YoY Change 574.42% -1.81%
Net Earnings / Revenue -44.01% -16.37%
Basic Earnings Per Share -$1.31
Diluted Earnings Per Share -$1.31 -$403.8K
COMMON SHARES
Basic Shares Outstanding 152.2M 73.01M
Diluted Shares Outstanding 152.2M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $722.6M $510.8M
YoY Change 41.48% 6.41%
Cash & Equivalents $720.1M $508.0M
Short-Term Investments $2.530M $2.819M
Other Short-Term Assets $73.00M $15.00M
YoY Change 386.67% 36.36%
Inventory $58.29M
Prepaid Expenses
Receivables $178.3M $70.70M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.032B $596.4M
YoY Change 73.09% 10.25%
LONG-TERM ASSETS
Property, Plant & Equipment $28.44M $10.09M
YoY Change 181.77% -72.72%
Goodwill $14.45B $734.4M
YoY Change 1867.9%
Intangibles $1.997B $214.7M
YoY Change 830.38%
Long-Term Investments
YoY Change
Other Assets $28.00M $15.33M
YoY Change 82.66% 1433.0%
Total Long-Term Assets $16.55B $1.007B
YoY Change 1544.07% -0.43%
TOTAL ASSETS
Total Short-Term Assets $1.032B $596.4M
Total Long-Term Assets $16.55B $1.007B
Total Assets $17.58B $1.603B
YoY Change 996.79% 3.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $34.38M $8.142M
YoY Change 322.22% 1.78%
Accrued Expenses $115.0M $54.00M
YoY Change 112.96% 31.71%
Deferred Revenue $17.87M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $260.4M $97.16M
YoY Change 167.96% 34.95%
LONG-TERM LIABILITIES
Long-Term Debt $1.363B $447.0M
YoY Change 204.92% 6.18%
Other Long-Term Liabilities $1.383M $10.24M
YoY Change -86.49% -63.44%
Total Long-Term Liabilities $1.383M $10.24M
YoY Change -86.49% -97.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $260.4M $97.16M
Total Long-Term Liabilities $1.383M $10.24M
Total Liabilities $261.7M $107.4M
YoY Change 143.71% -80.47%
SHAREHOLDERS EQUITY
Retained Earnings -$1.192B -$537.1M
YoY Change 121.98%
Common Stock $17.02B $1.572B
YoY Change 982.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.83B $1.000B
YoY Change
Total Liabilities & Shareholders Equity $17.58B $1.603B
YoY Change 996.79% 3.29%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$199.6M -$29.60M
YoY Change 574.42% -1.81%
Depreciation, Depletion And Amortization $48.66M $9.710M
YoY Change 401.12% -16.03%
Cash From Operating Activities -$18.03M -$6.320M
YoY Change 185.22% -19.92%
INVESTING ACTIVITIES
Capital Expenditures $2.115M $962.0K
YoY Change 119.85% 68.48%
Acquisitions $55.92M $9.000M
YoY Change 521.34%
Other Investing Activities -$3.150M $0.00
YoY Change -100.0%
Cash From Investing Activities -$16.03M -$11.93M
YoY Change 34.39% -262.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.18M 15.05M
YoY Change 47.31% 40.66%
NET CHANGE
Cash From Operating Activities -18.03M -6.320M
Cash From Investing Activities -16.03M -11.93M
Cash From Financing Activities 22.18M 15.05M
Net Change In Cash -11.88M -3.195M
YoY Change 271.86% -131.49%
FREE CASH FLOW
Cash From Operating Activities -$18.03M -$6.320M
Capital Expenditures $2.115M $962.0K
Free Cash Flow -$20.14M -$7.282M
YoY Change 176.59% -13.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
150281099
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154406164
CY2021Q1 tdoc Number Of Service Corporations Consolidated As Variable Interest Entities
NumberOfServiceCorporationsConsolidatedAsVariableInterestEntities
1
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P9M
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 tdoc Exercise Price Adjustment Ratio Closing Price Threshold Trading Days
ExercisePriceAdjustmentRatioClosingPriceThresholdTradingDays
P4D
CY2020Q4 tdoc Exercise Price Adjustment Ratio Closing Price Threshold Trading Days
ExercisePriceAdjustmentRatioClosingPriceThresholdTradingDays
P4D
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001477449
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-37477
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
TELADOC HEALTH, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3705970
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2 Manhattanville Road
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 203
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Purchase
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10577
CY2021Q1 dei City Area Code
CityAreaCode
203
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
635-2002
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
TDOC
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
154525777
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
720104000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
733324000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
2530000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
53245000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
8601000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6412000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
178341000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
169281000
CY2021Q1 us-gaap Inventory Net
InventoryNet
58290000
CY2020Q4 us-gaap Inventory Net
InventoryNet
56498000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
73065000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
47259000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
1032330000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1059607000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28436000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28551000
CY2021Q1 us-gaap Goodwill
Goodwill
14451975000
CY2020Q4 us-gaap Goodwill
Goodwill
14581255000
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1997214000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2020864000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44401000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46647000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
28002000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18357000
CY2021Q1 us-gaap Assets
Assets
17582358000
CY2020Q4 us-gaap Assets
Assets
17755281000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
34377000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
46030000
CY2021Q1 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
82397000
CY2020Q4 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
83657000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
59439000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
94593000
CY2021Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
70458000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
52356000
CY2021Q1 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
13693000
CY2020Q4 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
13453000
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
42560000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
260364000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
332649000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1383000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1616000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
40140000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
43142000
CY2021Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2716000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2449000
CY2021Q1 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
10404000
CY2020Q4 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
9926000
CY2021Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
84876000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
102103000
CY2021Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1352977000
CY2020Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1379592000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5026000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
18518000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
15829498000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15883804000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17582358000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17755281000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
453675000
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
180799000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
145959000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
72382000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154406164
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
150281099
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
154000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
150000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17016628000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
16857797000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1192310000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-992661000
CY2021Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
89439000
CY2020Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
32515000
CY2021Q1 us-gaap Selling Expense
SellingExpense
64793000
CY2020Q1 us-gaap Selling Expense
SellingExpense
17940000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78008000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19257000
CY2021Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
6323000
CY2020Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
3664000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
105172000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
46342000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
48659000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9710000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
538353000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
201810000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-84678000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21011000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-11459000
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5652000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-685000
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-22125000
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-8618000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-112610000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30314000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87039000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-711000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-199649000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-29603000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-13492000
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-17554000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-213141000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47157000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
152167606
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
73278857
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15883804000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11908000
CY2021Q1 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
CY2021Q1 tdoc Stock Retired During Period Value Related To Acquisition
StockRetiredDuringPeriodValueRelatedToAcquisition
40329000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
90000000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-13492000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-199649000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
15829498000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1014025000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14830000
CY2020Q1 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18421000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17554000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-29603000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
1000177000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-199649000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-29603000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
48659000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9710000
CY2021Q1 tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
824000
CY2020Q1 tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
0
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2948000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1518000
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3074000
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1247000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
86300000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
18315000
CY2021Q1 tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
87004000
CY2020Q1 tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-2820000
CY2021Q1 tdoc Accretion Of Interest
AccretionOfInterest
16829000
CY2020Q1 tdoc Accretion Of Interest
AccretionOfInterest
6859000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-11459000
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
5852000
CY2020Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-38000
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-105000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11717000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
17219000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12799000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-101000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2877000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1244000
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-137000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11989000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-502000
CY2021Q1 tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
-1889000
CY2020Q1 tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
26971000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-43624000
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-13798000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
17086000
CY2020Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5406000
CY2021Q1 tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3076000
CY2020Q1 tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1287000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-19000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-648000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18026000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6320000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2115000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
962000
CY2021Q1 us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
11144000
CY2020Q1 us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
1966000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
50000000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2021Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
55921000
CY2020Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
9000000
CY2021Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3150000
CY2020Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16030000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11928000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11908000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14889000
CY2021Q1 tdoc Payments For Repurchase Of Convertible Debt
PaymentsForRepurchaseOfConvertibleDebt
130000
CY2020Q1 tdoc Payments For Repurchase Of Convertible Debt
PaymentsForRepurchaseOfConvertibleDebt
0
CY2021Q1 tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
4816000
CY2020Q1 tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
0
CY2021Q1 tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
4098000
CY2020Q1 tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
0
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
8648000
CY2020Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0
CY2021Q1 tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
1218000
CY2020Q1 tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
164000
CY2021Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-187000
CY2020Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22175000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15053000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11881000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3195000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1339000
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3202000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
733324000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
514353000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
720104000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
507956000
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
52000
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021Q1 us-gaap Interest Paid
InterestPaid
3000
CY2020Q1 us-gaap Interest Paid
InterestPaid
0
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 1. Organization and Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">Teladoc, Inc. was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health” or the “Company”. The Company’s principal executive office is located in Purchase, New York. Teladoc Health is the global leader in providing virtual healthcare services with a focus on high quality, lower costs, and improved outcomes around the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">On January 4, 2021, the Company completed the acquisition of the UK-based telemedicine provider Consultant Connect Limited (“Consultant Connect”). Consultant Connect provides a platform that specializes in facilitating healthcare professional-to-professional advice and guidance in the United Kingdom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">On October 30, 2020, the Company completed the merger with Livongo Health, Inc. (“Livongo”), a transformational opportunity to improve the delivery, access and experience of healthcare for consumers around the world. Livongo is pioneering a new category in healthcare, called Applied Health Signals, which is transforming the management of chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On July 1, 2020, the Company completed the acquisition of InTouch Technologies, Inc. (“InTouch”), a leading provider of enterprise telehealth solutions for hospitals and health systems.</p>
CY2021Q1 tdoc Number Of Professional Associations Consolidated As Variable Interest Entities
NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities
3
CY2021Q1 tdoc Number Of Professional Corporations Consolidated As Variable Interest Entities
NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities
13
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), capitalization and amortization of software development costs, the finalization of purchase accounting adjustments, Client performance guarantees, the calculation of a contingent liability in connection with an acquisition earn-out, the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards and the periods of benefit for deferred costs as described in the Summary of Significant Accounting policies in this Quarterly Report and in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”).</p>
CY2021Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">Certain prior year amounts have been reclassified to conform to the current year presentation.</p>
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
453675000
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
180799000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
18400000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4800000
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
32700000
CY2020Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
8700000
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
62700000
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
4400000
CY2021Q1 tdoc Deferred Device Cost Current
DeferredDeviceCostCurrent
10950000
CY2020Q4 tdoc Deferred Device Cost Current
DeferredDeviceCostCurrent
3384000
CY2021Q1 tdoc Deferred Execution Credit Current
DeferredExecutionCreditCurrent
792000
CY2020Q4 tdoc Deferred Execution Credit Current
DeferredExecutionCreditCurrent
84000
CY2021Q1 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
11742000
CY2020Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
3468000
CY2021Q1 tdoc Deferred Device Cost Non Current
DeferredDeviceCostNonCurrent
6190000
CY2020Q4 tdoc Deferred Device Cost Non Current
DeferredDeviceCostNonCurrent
2179000
CY2021Q1 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
17932000
CY2020Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
5647000
CY2020Q4 tdoc Deferred Device Costs
DeferredDeviceCosts
5563000
CY2020Q4 tdoc Deferred Execution Credit
DeferredExecutionCredit
84000
CY2020Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
5647000
CY2021Q1 tdoc Deferred Device Costs Additions
DeferredDeviceCostsAdditions
13827000
CY2021Q1 tdoc Deferred Execution Credit Additions
DeferredExecutionCreditAdditions
820000
CY2021Q1 tdoc Deferred Device Cost And Other Additions
DeferredDeviceCostAndOtherAdditions
14647000
CY2021Q1 tdoc Deferred Device Cost Revenue Recognized
DeferredDeviceCostRevenueRecognized
0
CY2021Q1 tdoc Deferred Execution Credit Revenue Recognized
DeferredExecutionCreditRevenueRecognized
-112000
CY2021Q1 tdoc Deferred Device Cost And Other Revenue Recognized
DeferredDeviceCostAndOtherRevenueRecognized
-112000
CY2021Q1 tdoc Deferred Device Cost Cost Of Revenue Recognized
DeferredDeviceCostCostOfRevenueRecognized
-2250000
CY2021Q1 tdoc Deferred Execution Credit Cost Of Revenue Recognized
DeferredExecutionCreditCostOfRevenueRecognized
0
CY2021Q1 tdoc Deferred Device Cost And Other Cost Of Revenue Recognized
DeferredDeviceCostAndOtherCostOfRevenueRecognized
-2250000
CY2021Q1 tdoc Deferred Device Costs
DeferredDeviceCosts
17140000
CY2021Q1 tdoc Deferred Execution Credit
DeferredExecutionCredit
792000
CY2021Q1 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
17932000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87000000
CY2021Q1 us-gaap Inventory Raw Materials And Purchased Parts Net Of Reserves
InventoryRawMaterialsAndPurchasedPartsNetOfReserves
19202000
CY2020Q4 us-gaap Inventory Raw Materials And Purchased Parts Net Of Reserves
InventoryRawMaterialsAndPurchasedPartsNetOfReserves
19591000
CY2021Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1253000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1431000
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
37835000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
35476000
CY2021Q1 us-gaap Inventory Net
InventoryNet
58290000
CY2020Q4 us-gaap Inventory Net
InventoryNet
56498000
CY2021Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2205106000
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
207892000
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1997214000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2183399000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
162535000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2020864000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
46600000
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8900000
CY2020Q4 us-gaap Goodwill
Goodwill
14581255000
CY2019Q4 us-gaap Goodwill
Goodwill
746079000
CY2021Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
47328000
CY2020 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
13812198000
CY2021Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-61108000
CY2020 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
0
CY2021Q1 tdoc Goodwill Measurement Period Adjustment Deferred Taxes
GoodwillMeasurementPeriodAdjustmentDeferredTaxes
106532000
CY2020 tdoc Goodwill Measurement Period Adjustment Deferred Taxes
GoodwillMeasurementPeriodAdjustmentDeferredTaxes
0
CY2021Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-8968000
CY2020 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
22978000
CY2021Q1 us-gaap Goodwill
Goodwill
14451975000
CY2020Q4 us-gaap Goodwill
Goodwill
14581255000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3428000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4717000
CY2021Q1 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
10643000
CY2020Q4 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
23167000
CY2020Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2815000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11829000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11438000
CY2021Q1 tdoc Accrued Earn Out Current
AccruedEarnOutCurrent
4138000
CY2020Q4 tdoc Accrued Earn Out Current
AccruedEarnOutCurrent
4514000
CY2021Q1 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
5964000
CY2020Q4 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
7215000
CY2021Q1 us-gaap Litigation Reserve Current
LitigationReserveCurrent
1971000
CY2020Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
2419000
CY2021Q1 us-gaap Interest Payable Current
InterestPayableCurrent
7295000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2049000
CY2021Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4420000
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1627000
CY2021Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
5630000
CY2020Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
3139000
CY2021Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
4218000
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
22861000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20557000
CY2021Q1 tdoc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
82397000
CY2020Q4 tdoc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
83657000
CY2020Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
5000000
CY2021Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
5852000
CY2021Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
10852000
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
14589000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
14167000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
12840000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7962000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5744000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
4006000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
59308000
CY2021Q1 tdoc Advances From Financing Companies Customer Payments Due Current
AdvancesFromFinancingCompaniesCustomerPaymentsDueCurrent
10787000
CY2021Q1 tdoc Advances From Financing Companies Customer Payments Due Year One
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearOne
9624000
CY2021Q1 tdoc Advances From Financing Companies Customer Payments Due Year Two
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearTwo
3502000
CY2021Q1 tdoc Advances From Financing Companies Customer Payments Due Year Three
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearThree
185000
CY2021Q1 tdoc Advances From Financing Companies Customer Payments Due
AdvancesFromFinancingCompaniesCustomerPaymentsDue
24098000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
12229932
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0051
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
86300000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18315000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87000000.0
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-700000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87000000.0
CY2021Q1 tdoc Goodwill Measurement Period Adjustment Deferred Taxes
GoodwillMeasurementPeriodAdjustmentDeferredTaxes
106500000

Files In Submission

Name View Source Status
0001558370-21-005521-index-headers.html Edgar Link pending
0001558370-21-005521-index.html Edgar Link pending
0001558370-21-005521.txt Edgar Link pending
0001558370-21-005521-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tdoc-20210331.xsd Edgar Link pending
tdoc-20210331x10q.htm Edgar Link pending
tdoc-20210331x10q_htm.xml Edgar Link completed
tdoc-20210331xex10d1.htm Edgar Link pending
tdoc-20210331xex31d1.htm Edgar Link pending
tdoc-20210331xex31d2.htm Edgar Link pending
tdoc-20210331xex32d1.htm Edgar Link pending
tdoc-20210331xex32d2.htm Edgar Link pending
tdoc-20210331_cal.xml Edgar Link unprocessable
tdoc-20210331_def.xml Edgar Link unprocessable
tdoc-20210331_lab.xml Edgar Link unprocessable
tdoc-20210331_pre.xml Edgar Link unprocessable